Skip to main content
. Author manuscript; available in PMC: 2015 Mar 15.
Published in final edited form as: Clin Cancer Res. 2014 Jan 15;20(6):1698–1705. doi: 10.1158/1078-0432.CCR-13-2482

Figure 4.

Figure 4

Serial measurement of plasma genotype for disease monitoring. A wide dynamic range is seen in some cases (A, B). Decreases in plasma genotype can be seen both in cases of objective tumor shrinkage (A, D) and in cases of symptomatic response with no measurable disease (B, C). Concurrent EGFR L858R (A, solid line) and T790M (A, dashed line) mutations trend in parallel.